| pubmed-article:1881241 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1881241 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:1881241 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:1881241 | lifeskim:mentions | umls-concept:C0023820 | lld:lifeskim |
| pubmed-article:1881241 | lifeskim:mentions | umls-concept:C0017687 | lld:lifeskim |
| pubmed-article:1881241 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1881241 | lifeskim:mentions | umls-concept:C0486616 | lld:lifeskim |
| pubmed-article:1881241 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:1881241 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1881241 | pubmed:dateCreated | 1991-9-27 | lld:pubmed |
| pubmed-article:1881241 | pubmed:abstractText | Male adult Wistar rats received daily (at 9 a.m. and 5 p.m.) 10 micrograms of zinc-protamine glucagon by subcutaneous injection for 8 days. Plasma cholesterol levels were decreased by 36% in fed rats, 33% in cholesterol-fed rats and by 55% in fasted rats. Lipoproteins were separated into 22 fractions by ultracentrifugation using a density gradient. Glucagon administration decreased the cholesterol content in all lipoproteins except low density lipoprotein (LDL1) (1.006-1.040) and very low density lipoprotein (VLDL) from cholesterol-fed rats. The main decrease (-57 to -81%) was observed in 1.050-1.100 g/mL lipoproteins (LDL2 and HDL2), which contained a large amount of apo E, while HDL3 cholesterol was not affected. Triacylglycerol levels were decreased only in chylomicrons and VLDL (-70%) of fed and cholesterol-fed rats, while plasma and lipoprotein triacylglycerol levels were not changed in fasted rats treated with glucagon. In normally fed rats glucagon administration increased by 42% the fractional catabolic rate of [125I]HDL2 while the absolute catabolic rate appeared to be unchanged. Glucagon seems to be a potent hypolipidemic agent affecting mainly the apo E-rich lipoproteins. Its chronic administration limits lipoprotein accumulation which occurs upon cholesterol feeding. | lld:pubmed |
| pubmed-article:1881241 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1881241 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1881241 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1881241 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1881241 | pubmed:issn | 0024-4201 | lld:pubmed |
| pubmed-article:1881241 | pubmed:author | pubmed-author:JacototBB | lld:pubmed |
| pubmed-article:1881241 | pubmed:author | pubmed-author:NavarroNN | lld:pubmed |
| pubmed-article:1881241 | pubmed:author | pubmed-author:MathéDD | lld:pubmed |
| pubmed-article:1881241 | pubmed:author | pubmed-author:LecuyerBB | lld:pubmed |
| pubmed-article:1881241 | pubmed:author | pubmed-author:GuettetCC | lld:pubmed |
| pubmed-article:1881241 | pubmed:author | pubmed-author:RostaquiNN | lld:pubmed |
| pubmed-article:1881241 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1881241 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:1881241 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1881241 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1881241 | pubmed:pagination | 451-8 | lld:pubmed |
| pubmed-article:1881241 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:meshHeading | pubmed-meshheading:1881241-... | lld:pubmed |
| pubmed-article:1881241 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1881241 | pubmed:articleTitle | Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats. | lld:pubmed |
| pubmed-article:1881241 | pubmed:affiliation | Unité de Recherches sur les Dyslipidémies et l'Atherosclérose, INSERM U 32 Hôpital Henri-Mondor, Créteil, France. | lld:pubmed |
| pubmed-article:1881241 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1881241 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1881241 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1881241 | lld:pubmed |
